Glaukos announced that Health Canada has approved its iStent inject Trabecular Micro-Bypass Stent for the reduction of intraocular pressure (IOP) in patients diagnosed with primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma.
With this approval, the iStent inject can be used in combination with cataract surgery in patients who require IOP reduction and/or would benefit from glaucoma medication reduction. iStent inject is also indicated as a standalone procedure for patients who continue to have elevated IOP despite prior treatment with glaucoma medications or conventional glaucoma surgery.
The iStent inject relies on a similar fluidic method of action as the company’s flagship iStent Trabecular Micro-Bypass Stent, which was approved by Health Canada for use in combination with cataract surgery in 2009.
The iStent inject system includes an injector that delivers two preloaded stents, providing an ophthalmic surgeon the ability to target the placement of the stents through a single corneal entry point for greater IOP reduction.
Made from surgical-grade non-ferromagnetic titanium that is coated with heparin, each iStent inject stent is approximately 0.3 mm in diameter and 0.4 mm long, or roughly one-third the size of the original iStent.
Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) to address the shortcomings of conventional glaucoma treatment options, which include chronic use of daily prescription eye drops or invasive surgeries.
MIGS procedures involve insertion of a micro-scale device from within the eye’s anterior chamber to restore the natural outflow pathways for aqueous humor and provide sustained IOP reduction.
"The Health Canada approval of the iStent inject is another important advancement in the MIGS category," said Ike K. Ahmed, MD, FRCSC, Trillium Health Partners and University of Toronto.
As part of the approval process, Health Canada reviewed results of two investigational and three post-market studies. These five studies included 57 investigators in nine countries who implanted a total of 346 subjects with iStent inject. In one trial evaluating iStent inject as a standalone treatment, 66% of iStent inject subjects (n=58 of 88) achieved the primary endpoint of IOP = 18 mmHg at 12 months without medications.
The secondary endpoint, IOP = 18 mm Hg at 12 months regardless of medications, was achieved by 81% of iStent inject subjects (n=71 of 88). Furthermore, 72% of iStent inject subjects (n=63 of 88) experienced a = 20% IOP reduction without medications at 12 months.
The Glaucoma Research Society of Canada estimates that glaucoma affects more than 400,000 Canadians. Glaucoma is characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage. Open-angle glaucoma is the most common form of the disease. There is no cure for the glaucoma and reducing IOP is the only proven treatment.
"We are committed to remaining at the forefront of glaucoma innovation and are building a comprehensive portfolio of micro-scale injectable therapies that can serve the full spectrum of surgeon and patient needs," said Thomas Burns, president and CEO of Glaukos.
The iStent inject is already approved in the European Union and Australia. Glaukos is pursuing regulatory approval in additional markets, including the US where the company is conducting IDE clinical trials to evaluate two versions of the iStent inject, one in combination with cataract surgery and another as a standalone procedure in phakic and pseudophakic glaucoma patients.